We're lifting our price target on Cardinal Health after issuing rosy profit guidance

Cardinal Health reported Q4 revenue of $63.67B (+~6% YoY) which missed LSEG expectations ($65.03B), but adjusted EPS was $2.60 vs $2.42 consensus (a +18c beat; tariff refunds contributed 31c). For fiscal 2027, it guided adjusted earnings growth of 13%–15% to $12.40–$12.60 vs $12.04 expected, alongside free cash flow of $3.5B–$4.0B (vs $3.49B consensus). The stock rose >1% to a fresh record close ($239.71), and the firm raised its price target to $265 from $245 (maintaining a hold-equivalent 2 rating for now).

Analysis

Cardinal is behaving less like a low-growth distributor and more like a cash-flow compounder with operating leverage hidden in plain sight. The market is still underwriting it on legacy distribution economics, but the real re-rating engine is the mix shift toward specialty, at-home, and services businesses where incremental revenue converts at much higher margins. That should keep earnings revisions outpacing sales revisions over the next 1-3 months, which is the setup that usually sustains a multiple expansion even after a record run.

The near-term risk is that investors over-interpret one quarter’s beat while underweighting how much of the margin upside depends on contract economics and mix, not broad-based end-demand. A further pressure point is that lower drug acquisition prices can eventually flow through to distributor fee structures on renewal cycles; that is a 6-18 month risk, not a next-quarter issue. If CAH can hold guidance through the next couple of quarterly prints without needing further one-offs, the stock likely deserves to trade closer to higher-quality healthcare services names than to pure wholesalers.

Second-order winners are the suppliers and adjacent platforms tied to CAH’s higher-margin growth areas: specialty pharma ecosystems, home-delivery infrastructure, and outsourced practice-management. The contrarian miss in the market may be that the Street is still treating the business as mostly a volume pass-through; if so, estimates may continue to move up faster than consensus expects. The thesis breaks if core segment margin stalls once one-time benefits fade or if management is forced to concede lower compensation in renegotiations tied to price-capped drugs.

Key Decisions for Investors

• Buy CAH on 2-4% pullbacks; use a 3-6 month horizon and underwrite to estimate revisions rather than top-line growth. Risk/reward is attractive if the stock can re-rate toward a higher-quality distributor multiple, but trim if the next guide update slips below ~$12.40 EPS.
• Pair trade: long CAH / short MCK over the next 1-3 months if you want to express the view that CAH’s margin mix is underappreciated relative to peers. Falsifier: if CAH’s specialty and at-home growth decelerate while peers reaccelerate, the pair should be unwound.
• For option exposure, consider a CAH call spread 3-6 months out instead of chasing the common after a record close. This limits downside if the market has already priced in most of the guidance upside while preserving participation in a post-earnings estimate-revision drift.
• Watch JNJ and LLY only as indirect beneficiaries of a more efficient drug-distribution ecosystem; no immediate catalyst trade is required. Reassess if pharma contract resets start compressing distributor economics, which would be the first sign that CAH’s service-fee insulation is weakening.